Top Deck Moves At Ranbaxy: Jay Deshmukh, Architect Of Lipitor And Nexium Patent Challenge Quits, R&D Head Himadri Sen Turns Advisor
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Japanese drug maker Daiichi Sankyo's acquisition of India's largest company - Ranbaxy - could result in a few structural changes in the company's top management team
You may also be interested in...
Ranbaxy and Pfizer Settle Lipitor Litigation
MUMBAI - Ranbaxy Laboratories said on June 18 that it has settled most of the patent litigations involving Lipitor (atorvastatin) with Pfizer, putting an end to a five-year legal battle between the two companies
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).